BAM
EDIT icon

Brave Asset Management’s Editas Medicine EDIT Stock Holding History

Brave Asset Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,000
Closed -$55K – 177
2025
Q2 		$55K Sell
25,000
-10,000
-29% -$16.4K 0.01% 155
2025
Q1 		$40.6K Buy
35,000
+25,000
+250% +$36.8K 0.01% 150
2024
Q4 		$12.7K Sell
10,000
-725
-7% -$1.85K ﹤0.01% 162
2024
Q3 		$36.6K Hold
10,725
– – 0.01% 157
2024
Q2 		$50.1K Hold
10,725
– – 0.01% 144
2024
Q1 		$79.6K Hold
10,725
– – 0.02% 144
2023
Q4 		$109K Hold
10,725
– – 0.03% 137
2023
Q3 		$83.7K Hold
10,725
– – 0.03% 132
2023
Q2 		$88.3K Buy
+10,725
New +$93.4K 0.03% 135

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Brave Asset Management's EDIT Position: Q3 2025 in Review

Brave Asset Management sold out of Editas Medicine (EDIT) in Q3 2025, closing a stake of 25,000 shares — an estimated $55K sold.

Brave Asset Management first reported a position in EDIT in Q2 2023 and held it in 9 quarters. The position peaked at $109K in Q4 2023. 193 funds tracked by Wall St. Rank hold EDIT as of Q3 2025.

  • Brave Asset Management reported no remaining Editas Medicine position as of Q3 2025 after selling out during the quarter.
  • Brave Asset Management sold 25,000 Editas Medicine shares in Q3 2025, an estimated $55K.
  • Brave Asset Management first reported a position in Editas Medicine in Q2 2023 and held it in 9 quarters.
  • Brave Asset Management's Editas Medicine position peaked at $109K in Q4 2023.
  • 193 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2025.

Based on Brave Asset Management's 13F filing for Q3 2025, filed 21 Oct 2025.